Results 91 to 100 of about 427 (170)

Retrospective analysis of predictive factors for epithelial-mesenchymal histological discordance following neoadjuvant chemotherapy in pleural mesothelioma

reservedScopo dello Studio: Scopo del nostro studio retrospettivo monocentrico è di individuare possibili fattori clinici e radiologici predittivi di una discordanza istologica epitelio-mesenchimale dopo trattamento chemioterapico ad intento ...
ZAMBELLO, GIOVANNI
core  

Malignant Peritoneal Mesothelioma as a Rare Cause of Dyspeptic Complaints and Ascites: A Diagnostic Challenge. [PDF]

GE Port J Gastroenterol, 2020
Marques de Sousa S, Pereira F, Duarte M, Marques M, Vázquez D, Marques C.   +5 more
europepmc   +1 more source

Chemotherapy treatment of malignant pleural mesothelioma: a systematic review

, 2015
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil.Contexto - O mesotelioma pleural maligno é um tipo de câncer raro, agressivo e com uma expectativa de aumento na incidência até 2030. As melhores formas de
Souza, André de Oliveira
core  

Mesotelioma pleural secundario a radioterapia: una asociación infrecuente

Archivos de Bronconeumología, 2012
Leiro Fernández, Virginia, Fernández Villar, José Alberto, Lourido Cebreiro, Tamara   +2 more
openaire   +2 more sources

Malignant Pleural Mesothelioma: Analysis of 70 Cases in the Last Decade. [PDF]

Open Respir Arch
Garcia-Prieto F, Pardo SC, Ramírez MTR, Fernández AA.   +3 more
europepmc   +1 more source

Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights. [PDF]

Open Respir Arch
López-Castro R, Fuentes-Martín Á, Medina Del Valle A, García Peña T, Soro García J, López González L, Cilleruelo Ramos Á.   +6 more
europepmc   +1 more source

Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. [PDF]

BJS Open, 2021
Zahid A, Clarke L, Carr N, Chandrakumaran K, Tzivanakis A, Dayal S, Mohamed F, Cecil T, Moran BJ.   +8 more
europepmc   +1 more source

Mesothelioma and Social Security Benefits in Brazil: 2019 to 2021. [PDF]

Rev Bras Med Trab
Gomes LEFE, Souza NSS.
europepmc   +1 more source

Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis. [PDF]

J Cancer Res Clin Oncol, 2021
Carosio R, Fontana V, Mastracci L, Ferro P, Grillo F, Banelli B, Canessa PA, Dessanti P, Vigani A, Morabito A, Pfeffer U, Poggi A, Roncella S, Pistillo MP.   +13 more
europepmc   +1 more source